Synonym
LY 517717; LY517717; LY-517717
IUPAC/Chemical Name
(R)-N-(2-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-2-oxo-1-phenylethyl)-1H-indole-6-carboxamide
InChi Key
VYNKVNDKAOGAAQ-RUZDIDTESA-N
InChi Code
InChI=1S/C27H33N5O2/c1-30-13-10-23(11-14-30)31-15-17-32(18-16-31)27(34)25(21-5-3-2-4-6-21)29-26(33)22-8-7-20-9-12-28-24(20)19-22/h2-9,12,19,23,25,28H,10-11,13-18H2,1H3,(H,29,33)/t25-/m1/s1
SMILES Code
O=C(C1=CC2=C(C=C1)C=CN2)N[C@H](C3=CC=CC=C3)C(N4CCN(C5CCN(C)CC5)CC4)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
LY 517717 is a coagulation factor Xa inhibitor.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
459.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Agnelli G, Haas S, Ginsberg JS, Krueger KA, Dmitrienko A, Brandt JT. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost. 2007 Apr;5(4):746-53. PubMed PMID: 17408408.
2: Perzborn E. Factor Xa inhibitors--new anticoagulants for secondary haemostasis. Hamostaseologie. 2009 Aug;29(3):260-7. PubMed PMID: 19644596.
3: Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1238-47. Review. PubMed PMID: 17379841.
4: Denas G, Pengo V. Investigational anticoagulants for hematological conditions: a new generation of therapies. Expert Opin Investig Drugs. 2013 Oct;22(10):1281-94. doi: 10.1517/13543784.2013.821463. Review. PubMed PMID: 23876036.
5: Ahrens I, Peter K, Lip GY, Bode C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med. 2012 Jun;13(73):445-50. Review. PubMed PMID: 22742650.
6: Bondarenko M, Curti C, Montana M, Rathelot P, Vanelle P. Efficacy and toxicity of factor Xa inhibitors. J Pharm Pharm Sci. 2013;16(1):74-88. Review. PubMed PMID: 23683607.
7: Romualdi E, Ageno W. Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. Expert Opin Investig Drugs. 2011 Apr;20(4):495-505. doi: 10.1517/13543784.2011.562190. Review. PubMed PMID: 21385107.
8: Norman P. Fragments 2007--what has fragment-based drug discovery delivered for medicinal chemistry? 7 March 2007, Cambridge, UK. IDrugs. 2007 May;10(5):313-6. PubMed PMID: 17487781.
9: Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost. 2008 Feb;34(1):39-57. doi: 10.1055/s-2008-1066023. Review. PubMed PMID: 18393142.
10: Imberti D, Dall'Asta C, Pierfranceschi MG. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. Review. PubMed PMID: 19696978.
11: Hampton T. New oral anticoagulants show promise. JAMA. 2006 Feb 15;295(7):743-4. PubMed PMID: 16478891.
12: Imberti D, Prisco D. Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review. Pathophysiol Haemost Thromb. 2008;36(5):217-26. doi: 10.1159/000252816. Review. PubMed PMID: 19996630.
13: Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008 Jan;29(2):155-65. Review. PubMed PMID: 18096568.
14: Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006 Aug;15(8):843-55. Review. PubMed PMID: 16859389.
